Wockhardt shares rise 10% after Zaynich aids successful liver transplant trial
Wockhardt's shares surged 8.6% after its antibiotic Zaynich successfully treated a US cancer patient, enabling a liver transplant and chemotherapy. The drug is nearing Phase III trials for global approval.
Site référencé: The Economic Times
The Economic Times
ICICI Bank, HPCL among 90 stocks with record dates for dividends, splits, bonus next week
9/08/2025
Avoid bottom-fishing in PG Electroplast shares, CDSL among 3 ideas for next week : Rupak De
9/08/2025
Wealth creation boom ahead as India’s growth cycle picks up pace, says Vikas Khemani
9/08/2025
What should fixed income investors do post RBI Monetary Policy Meeting
9/08/2025
NSDL pre-IPO investors finally make money as stock up 62% in 3 days
9/08/2025
From fall to flight : 7 smallcap stocks stage a strong comeback in 2025
9/08/2025
